PMID- 26821720
OWN - NLM
STAT- MEDLINE
DCOM- 20160801
LR  - 20210504
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 128
IP  - 3
DP  - 2016
TI  - The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 
      inhibitors.
PG  - 290-8
LID - 10.1080/00325481.2016.1147926 [doi]
AB  - Understanding the role of the kidneys in type 2 diabetes mellitus (T2DM) has 
      taken on an increased importance in recent years with the arrival of 
      sodium-glucose co-transporter 2 (SGLT2) inhibitors - antihyperglycemic agents 
      (AHAs) that specifically target the kidneys. This review includes an update on 
      the physiology of the kidneys, their role in the pathophysiology of T2DM, and the 
      mechanisms implicated in the development and progression of diabetic kidney 
      disease, such as glomerular hyperfiltration and inflammation. It also discusses 
      renal issues that could influence the choice of AHA for patients with T2DM, 
      including special populations such as patients with concomitant chronic kidney 
      disease. The most recent data published on the clinical efficacy and safety of 
      the SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin and their 
      effects on renal function are presented, showing how the renally mediated 
      mechanisms of action of these agents translate into clinical benefits, including 
      the potential for renoprotection. The observed positive effects of these agents 
      on measures such as glucose control, estimated glomerular filtration rate, 
      albumin-to-creatinine ratio, blood pressure, and body weight in patients both 
      with and without impaired renal function suggest that SGLT2 inhibitors represent 
      an important extension to the diabetes treatment armamentarium.
FAU - Weir, Matthew R
AU  - Weir MR
AD  - a Division of Nephrology, Department of Medicine , University of Maryland School 
      of Medicine , Baltimore , MD , USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160219
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - AYI8EX34EU (Creatinine)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Albuminuria
MH  - Benzhydryl Compounds/*therapeutic use
MH  - Canagliflozin/*therapeutic use
MH  - Creatinine/metabolism
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/metabolism
MH  - Diabetic Nephropathies/etiology/metabolism
MH  - Glomerular Filtration Rate
MH  - Glucosides/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Kidney/*metabolism
MH  - Renal Insufficiency, Chronic/etiology/metabolism
MH  - *Sodium-Glucose Transporter 2 Inhibitors
OTO - NOTNLM
OT  - Kidney
OT  - Nephropathy
OT  - Pathophysiology
OT  - SGLT2
OT  - Sodium-glucose co-transporter 2
OT  - T2DM
OT  - Type 2 diabetes mellitus
EDAT- 2016/01/30 06:00
MHDA- 2016/08/02 06:00
CRDT- 2016/01/30 06:00
PHST- 2016/01/30 06:00 [entrez]
PHST- 2016/01/30 06:00 [pubmed]
PHST- 2016/08/02 06:00 [medline]
AID - 10.1080/00325481.2016.1147926 [doi]
PST - ppublish
SO  - Postgrad Med. 2016;128(3):290-8. doi: 10.1080/00325481.2016.1147926. Epub 2016 
      Feb 19.